David Amsellem
Stock Analyst at Piper Sandler
(4.80)
# 114
Out of 5,006 analysts
152
Total ratings
65.83%
Success rate
23.99%
Average return
Main Sectors:
Stocks Rated by David Amsellem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SUPN Supernus Pharmaceuticals | Maintains: Neutral | $36 → $40 | $48.31 | -17.20% | 16 | Aug 29, 2025 | |
| AMGN Amgen | Maintains: Overweight | $328 → $342 | $294.12 | +16.28% | 5 | Aug 25, 2025 | |
| BIIB Biogen | Maintains: Neutral | $115 → $118 | $154.05 | -23.40% | 2 | Aug 14, 2025 | |
| ABBV AbbVie | Assumes: Overweight | $231 | $230.19 | +0.35% | 1 | Aug 12, 2025 | |
| AMPH Amphastar Pharmaceuticals | Maintains: Neutral | $30 → $25 | $26.59 | -5.98% | 9 | Aug 8, 2025 | |
| CORT Corcept Therapeutics | Maintains: Overweight | $131 → $121 | $89.85 | +34.67% | 8 | Aug 1, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Overweight | $154 → $175 | $139.43 | +25.51% | 11 | Jul 31, 2025 | |
| OGN Organon & Co. | Maintains: Overweight | $24 → $18 | $10.84 | +66.05% | 6 | May 15, 2025 | |
| COLL Collegium Pharmaceutical | Reiterates: Neutral | $36 → $37 | $33.83 | +9.37% | 8 | May 9, 2025 | |
| JAZZ Jazz Pharmaceuticals | Reiterates: Overweight | $176 → $147 | $137.58 | +6.85% | 14 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $65 | $45.14 | +44.00% | 1 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $3 → $4 | $8.13 | -50.80% | 5 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $13 | $22.76 | -42.88% | 5 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $14 → $10 | $10.13 | -1.28% | 7 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $30 | $19.96 | +50.30% | 10 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $13 | $14.53 | -10.53% | 5 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $11 | $10.55 | +4.27% | 4 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $38 → $37 | $30.99 | +19.39% | 7 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $68 | $92.06 | -26.14% | 1 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $9 → $3 | $6.47 | -53.63% | 7 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 | $23.87 | +75.95% | 10 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $10 | $5.97 | +67.50% | 1 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $21 | $1.48 | +1,318.92% | 3 | Feb 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $90 → $113 | $119.94 | -5.79% | 3 | Jan 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $42 | $26.59 | +57.95% | 3 | Oct 16, 2023 |
Supernus Pharmaceuticals
Aug 29, 2025
Maintains: Neutral
Price Target: $36 → $40
Current: $48.31
Upside: -17.20%
Amgen
Aug 25, 2025
Maintains: Overweight
Price Target: $328 → $342
Current: $294.12
Upside: +16.28%
Biogen
Aug 14, 2025
Maintains: Neutral
Price Target: $115 → $118
Current: $154.05
Upside: -23.40%
AbbVie
Aug 12, 2025
Assumes: Overweight
Price Target: $231
Current: $230.19
Upside: +0.35%
Amphastar Pharmaceuticals
Aug 8, 2025
Maintains: Neutral
Price Target: $30 → $25
Current: $26.59
Upside: -5.98%
Corcept Therapeutics
Aug 1, 2025
Maintains: Overweight
Price Target: $131 → $121
Current: $89.85
Upside: +34.67%
Neurocrine Biosciences
Jul 31, 2025
Maintains: Overweight
Price Target: $154 → $175
Current: $139.43
Upside: +25.51%
Organon & Co.
May 15, 2025
Maintains: Overweight
Price Target: $24 → $18
Current: $10.84
Upside: +66.05%
Collegium Pharmaceutical
May 9, 2025
Reiterates: Neutral
Price Target: $36 → $37
Current: $33.83
Upside: +9.37%
Jazz Pharmaceuticals
May 7, 2025
Reiterates: Overweight
Price Target: $176 → $147
Current: $137.58
Upside: +6.85%
Apr 22, 2025
Initiates: Overweight
Price Target: $65
Current: $45.14
Upside: +44.00%
Mar 7, 2025
Reiterates: Neutral
Price Target: $3 → $4
Current: $8.13
Upside: -50.80%
Mar 6, 2025
Maintains: Overweight
Price Target: $16 → $13
Current: $22.76
Upside: -42.88%
Mar 5, 2025
Reiterates: Neutral
Price Target: $14 → $10
Current: $10.13
Upside: -1.28%
Jan 17, 2025
Maintains: Overweight
Price Target: $23 → $30
Current: $19.96
Upside: +50.30%
Jan 10, 2025
Maintains: Overweight
Price Target: $24 → $13
Current: $14.53
Upside: -10.53%
Nov 11, 2024
Maintains: Overweight
Price Target: $9 → $11
Current: $10.55
Upside: +4.27%
Oct 25, 2024
Reiterates: Overweight
Price Target: $38 → $37
Current: $30.99
Upside: +19.39%
Oct 11, 2024
Initiates: Overweight
Price Target: $68
Current: $92.06
Upside: -26.14%
Aug 2, 2024
Downgrades: Underweight
Price Target: $9 → $3
Current: $6.47
Upside: -53.63%
Jul 3, 2024
Maintains: Overweight
Price Target: $42
Current: $23.87
Upside: +75.95%
Apr 11, 2024
Initiates: Overweight
Price Target: $10
Current: $5.97
Upside: +67.50%
Feb 16, 2024
Maintains: Overweight
Price Target: $20 → $21
Current: $1.48
Upside: +1,318.92%
Jan 16, 2024
Maintains: Overweight
Price Target: $90 → $113
Current: $119.94
Upside: -5.79%
Oct 16, 2023
Maintains: Overweight
Price Target: $72 → $42
Current: $26.59
Upside: +57.95%